Российский кардиологический журнал (Oct 2017)

CLINICAL PORTRAIT OF THE ATRIAL FIBRILLATION PATIENT IN Russian FEDERATION. DATA FROM THE GLOBAL REGISTRY Gloria AF

  • E. V. Shlyakhto,
  • А. V. Ezhov,
  • S. А. Zenin,
  • N. А. Koziolova,
  • О. Yu. Korennova,
  • Т. N. Novikova,
  • К. V. Protasov,
  • М. N. Sumin,
  • G. А. Chumakova,
  • G. Y. H. Lip,
  • M. V. Huisman,
  • K. J. Rothman

DOI
https://doi.org/10.15829/1560-4071-2017-9-138-142
Journal volume & issue
Vol. 0, no. 9
pp. 21 – 27

Abstract

Read online

Aim. To analyze clinical specifics of the Russian population of non-valvular atrial fibrillation patients participating in the 2nd phase of international registry Gloria AF.Material and methods. The data on clinical characteristics presented, of the Russian population of atrial fibrillation patients, gathered in the second phase of Gloria AF study. The study is an international prospective observational program representing the registry of patients with the first time diagnosed atrial fibrillation. Results. Most patients included into Russian population of the Gloria AF registry had one or several comorbidities: 93,6% had arterial hypertension, 37,4% — coronary heart disease, 14,4% — myocardial infarction in anamnesis. Nineteen and three percent of patients had diabetes, 56,4% — chronic heart failure, 8,7% had stroke in anamnesis. Stroke risk assessment showed that the average score by CHA2 DS2 -VASc was 3,2 points, and 14,4% had the risk as 1 pt, 86,6% — two and more points. Such profile of risk was comparable with the data from general population of Gloria AF, and close to those from Garfield registry. Antithrombotic therapy profile analysis points on an intensive implementation of the Novel Oral Anticoagulants into real clinical practice of the investigative centers participating in the Gloria AF.Conclusion. The results witness on comparable with the international data risk profile in Russian Federation population of AF patients included into the second phase of Gloria AF registry, as on an intensive implementation of the new class Novel Oral Anticoagulants into routine clinical practice of research centers participating in the registry.

Keywords